Evidence map›Paper›PMID 19004030›Full record

ArticleThe Journal of rheumatology2008

MAGE-B2 autoantibody: a new biomarker for pediatric systemic lupus erythematosus.

Alice D C Hoftman, Lei-Qian Tai, Sheila Tze, David Seligson, Richard A Gatti, Deborah K McCurdy

Open access · bronzeAbstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of rheumatology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
0.6field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 12 citations in OpenAlex.

  1. Serum tests for colorectal cancer screening.Molecular diagnosis & therapy · 2011
    Pooled it
  2. Role(s) of G3BPs in Human Pathogenesis.The Journal of pharmacology and experimental therapeutics · 2023
    Review
  3. Review
  4. Review
  5. Biomarkers for lupus nephritis: a critical appraisal.Journal of biomedicine & biotechnology · 2010
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Alice D C HoftmanDivision of Allergy, Immunology, and Rheumatology, Department of Pediatrics, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA.
Lei-Qian Tai
Sheila Tze
David Seligson
Richard A Gatti
Deborah K McCurdy
Children's Hospital of Orange County · USUniversity of California, Los Angeles · US

Funding

HUMAN AND MOLECULAR DEVELOPMENT TRAINING PROGRAMT32HD007512 · NICHD · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI DEVASKAR, SHERIN U · 1998 to 2012
$2.6M
Academic Training in RheumatologyT32AR053463 · NIAMS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI SINGH, RAM RAJ · 2007 to 2011
$1.1M
NIAMS NIH HHS 1T32AR053463NIAMS NIH HHS T32 AR053463NICHD NIH HHS T32 HD007512NICHD NIH HHS T32 HD07512
6 · The paper itself

Abstract

objectiveMelanoma-associated antigen gene B2 (MAGE-B2) encodes an embryonic antigen normally silenced after birth except in testis and placenta. We identified the MAGE-B2 gene and autoantibodies in pediatric patients with systemic lupus erythematosus (SLE) glomerulonephritis. We investigated the prevalence of MAGE-B2 autoantibodies in association with active SLE, to determine a pathogenetic role of MAGE-B2 protein through its distribution in cells and tissues.

methodsA cross-sectional study analyzed the frequency of MAGE-B2 autoantibodies in 40 patients with pediatric SLE, 23 adult controls, and 16 patients with pediatric juvenile rheumatoid arthritis (JRA) using Western blots containing recombinant MAGE-B2. SLE Disease Activity Index 2000 (SLEDAI-2K) and British Isles Lupus Assessment Group (BILAG) index measured SLE disease activity. Tissue distribution of MAGE-B2 protein was assessed by immunohistochemistry, immunofluorescence, and Western blots.

resultsSeventeen (43%) of 40 pediatric SLE patients had MAGE-B2 autoantibodies as compared to 0 of 16 JRA patients and 2 of 23 adult controls. SLE disease activity was significantly higher in MAGE-B2 autoantibody-positive versus autoantibody-negative patients (SLEDAI-2K, mean 10.9 vs 5.2, p = 0.013; BILAG, mean 15.3 vs 6.3, p = 0.023). Active nephritis was more prevalent (60% vs 24%) in MAGE-B2 autoantibody-positive than autoantibody-negative SLE patients. MAGE-B2 protein was visualized in SLE kidney proximal convoluted tubules and in tumor epithelial cells, but not in lymphoblastoid cells.

conclusionMAGE-B2 autoantibody appears to be a clinically relevant biomarker for pediatric SLE disease activity and nephritis.

Indexed as

AdolescentAntigens, NeoplasmArthritis, JuvenileAutoantibodiesBiomarkersCase-Control StudiesChildChild, PreschoolCross-Sectional StudiesFemaleHumansLupus NephritisMaleNeoplasm ProteinsSeverity of Illness IndexYoung AdultAntigens, NeoplasmAutoantibodiesBiomarkersMAGEB2 protein, humanNeoplasm Proteins

Identifiers

PMID19004030
PMCPMC2765927
OpenAlexW2066063579

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.